Filgrastim

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.3. Immunomodulators

EMLc Codes ATC: L03AA02

Indication	Acquired neutropaenia Code ICD11: 4B00.01
INN	Filgrastim
Type de médicament	Biological agent
Type de liste	Liste complémentaire
Additional notes	Including quality-assured biosimilars.
Formulations	**Parenteral > General injections > SC:** 120 µg per 0.2 mL in prefilled syringe ; 300 µg per 0.5 mL in prefilled syringe ; 480 µg per 0.8 mL in prefilled syringe ; 300 µg per mL in 1 mL vial ; 480 µg per 1.6 mL in 1.6 mL vial
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Balises	Cancer Biological
Wikipédia	Filgrastim
DrugBank	Filgrastim

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, filgrastim, a granulocyte colony stimulating factor, was added to the complementary list of the EML and EMLc for use in the following indications: - primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy; - secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy; - to facilitate administration of dose dense chemotherapy regimens. The relevant extract from TRS994 regarding the Expert Committee's consideration of G-CSF is attached.